Article Text

Download PDFPDF

863 Novel radioimmunotherapy for lung cancer: a tumor targeting approach
  1. Céline Godfroid1,
  2. Jackeline Romero2,
  3. Vincent Roh3,
  4. Tania Wyss4,
  5. Sara Labiano5,
  6. Christian Klein6,
  7. Laura Codarri Deak6,
  8. Pablo Umaña6,
  9. Genrich V Tolstonog1,7,
  10. Christine Trumpfheller6,
  11. Marie-Catherine Vozenin2 and
  12. Pedro Romero8
  1. 1University of Lausanne, Lausanne, Switzerland
  2. 2Laboratory of Radiation Oncology, Department of Radiation Oncology, Lausanne University Hospital and University of Lausanne, Epalinges, Switzerland
  3. 3Swiss Institute of Bioinformatics, Lausanne, Switzerland
  4. 4Department of Oncology, University of Lausanne, Epalinges, Switzerland
  5. 5Department of Pediatrics, University of Navarra Clinic (CUN), Pamplona, Spain
  6. 6Roche Innovation Center Zurich (RICZ), Roche Pharmaceutical Research and Early Development (pRED), Schlieren, Switzerland
  7. 7Department of Otolaryngology – Head and Neck Surgery, Lausanne University Hospital, Lausanne, Switzerland
  8. 8Novigenix SA, Epalinges, Switzerland
  • Journal for ImmunoTherapy of Cancer (JITC) preprint. The copyright holder for this preprint are the authors/funders, who have granted JITC permission to display the preprint. All rights reserved. No reuse allowed without permission.


Background Novel efficient therapeutic options for lung carcinoma are needed as the survival at 5 years of metastatic disease treated by the standard of care is near zero.

Methods In this regard, we used a novel preclinical model of lung adenocarcinoma to assess the safety and efficacy of radio-immunotherapy combining local hypofractionated radiotherapy with tumor-stroma targeted FAP-CD40 agonistic bispecific antibody and PD1-IL2v immunocytokine.

Results In this model, combination treatments using hypofractionated RT + anti-FAP-CD40 and/or anti-PD1-IL2v mediate tumor growth retardation and extend mouse survival compared with radiotherapy alone or immunotherapy used as a single agent. Importantly, they were devoid of measurable toxicity. The best anti-tumor activity was obtained with the RT + anti-PD1-IL2v and RT + anti-FAP-CD40 + anti-PD1-IL2v combinations. In these treatment groups, survival of mice was extended more than 30 days (60 days post tumor engraftment) compared to the control cohorts. Immuno pharmacodynamic analysis and immunofluorescence data in these groups show that treatment with radiotherapy and anti-PD1-IL2v + anti-FAP-CD40 associates with increases in the endogenous CD8 T cells and transferred OT-1 infiltrating the lungs. The anti-tumor activity of the anti-PD1-IL2v monotherapy required CD8 T cells as suggested by immune cell depletion experiments. Additionally, the SV2 lung adenocarcinoma cell line has been transduced with a library of barcodes to study clonal dynamics of tumor cells during disease progression and therapy.

Conclusions The results of our preclinical study warrant and inform the translation and clinical testing of these novel immunotherapeutic agents in patients with metastatic lung adenocarcinoma.

Ethics Approval All animal procedures were carried out under the license VD3173.1c which was approved by the Veterinary Authority of the Swiss Canton of Vaud.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.